Sangamo Therapeutics (NASDAQ: CSBR) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Sangamo Therapeutics and Champions Oncology, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sangamo Therapeutics 0 1 5 0 2.83
Champions Oncology 0 0 3 0 3.00

Sangamo Therapeutics presently has a consensus price target of $21.40, suggesting a potential upside of 44.11%. Champions Oncology has a consensus price target of $11.00, suggesting a potential upside of 3.97%. Given Sangamo Therapeutics’ higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Champions Oncology.

Earnings & Valuation

This table compares Sangamo Therapeutics and Champions Oncology’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sangamo Therapeutics $36.57 million 41.29 -$54.56 million ($0.70) -21.21
Champions Oncology $20.24 million 5.77 -$1.47 million ($0.14) -75.57

Champions Oncology has lower revenue, but higher earnings than Sangamo Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Sangamo Therapeutics and Champions Oncology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sangamo Therapeutics -105.65% -26.36% -17.00%
Champions Oncology -7.44% -531.69% -21.43%

Volatility and Risk

Sangamo Therapeutics has a beta of 2.95, indicating that its stock price is 195% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.

Institutional & Insider Ownership

64.0% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 38.9% of Champions Oncology shares are held by institutional investors. 1.2% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 44.3% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


Sangamo Therapeutics beats Champions Oncology on 8 of the 13 factors compared between the two stocks.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); preclinical programs in other LSDs; and research stage programs in central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and Shire International GmbH to develop the preclinical development program in Huntington's disease, as well as license agreements with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells and plants. The company also has a research collaboration and license agreement with Pfizer Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.

About Champions Oncology

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies that use vivo studies, which rely on implanting multiple tumors from TumorBank in mice and testing the therapy of interest on tumors. The company markets its products through Internet, word of mouth, and a network of sales force to patients and physicians. Champions Oncology, Inc. has collaboration agreements with The Addario Lung Cancer Medical Institute and AstraZeneca to develop cohorts of PDX models. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with's FREE daily email newsletter.